<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; good</title>
	<atom:link href="http://www.tapanray.in/tag/good/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>PE Investment In Pharma: The Changing Need Of Due Diligence</title>
		<link>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pe-investment-in-pharma-the-changing-need-of-due-diligence</link>
		<comments>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/#comments</comments>
		<pubDate>Mon, 02 May 2016 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[due diligence]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[PE]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[promoters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7621</guid>
		<description><![CDATA[From an international perspective, a Bain &#38; Company report of April 2016 highlighted setting a new healthcare M&#38;A record in the year 2015. During this year the total deal value was over 2.5 times higher than the average annual deal value &#8230; <a href="http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets</title>
		<link>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets</link>
		<comments>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/#comments</comments>
		<pubDate>Mon, 01 Jul 2013 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Argentina]]></category>
		<category><![CDATA[Balancing]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[bouquets]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[brickbats]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Carlos]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Correa]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Leash]]></category>
		<category><![CDATA[Leashing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[power play]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reasonably]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[Section2(ja)]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[wasteful]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WOW]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2691</guid>
		<description><![CDATA[It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve &#8230; <a href="http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescribing medicines by generic names…a good intent… but is it a practical proposition in India?</title>
		<link>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india</link>
		<comments>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/#comments</comments>
		<pubDate>Mon, 06 Sep 2010 00:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[chemists]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practical]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proposition]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=378</guid>
		<description><![CDATA[Parliamentary Standing Committee for Health and Family Welfare in their recommendation to the ‘Rajya Sabha’ of the Indian Parliament on August 4, 2010, recommended prescription of medicines by their generic names. This recommendation appears to be based on the premises &#8230; <a href="http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
